An open-label, randomized positron emission tomography (PET)study in healthy male volunteers consisiting of Part A and Part B.Part A: Clinical validation of norepinephrine transporter (NET) PET ligand, (S,S)-[11C]O-methylreboxetine ([11C]MRB) using different doses of oral atomoxetine as NET reuptake inhibitor.Part B: Evaluation of NET occupancy, as measured by [11C]MRB, with multiple dosing regimens of orally administered GSK372475. | Zendy

Joanna S. Fowler | Zendy; Michael Furey | Zendy

Open Access

An open-label, randomized positron emission tomography (PET)study in healthy male volunteers consisiting of Part A and Part B.Part A: Clinical validation of norepinephrine transporter (NET) PET ligand, (S,S)-[11C]O-methylreboxetine ([11C]MRB) using different doses of oral atomoxetine as NET reuptake inhibitor.Part B: Evaluation of NET occupancy, as measured by [11C]MRB, with multiple dosing regimens of orally administered GSK372475.

Author(s) -

Joanna S. Fowler,

Michael Furey

Publication year - 2007

Publication title -

osti oai (u.s. department of energy office of scientific and technical information)

Language(s) - English

Resource type - Reports

DOI - 10.2172/973576

Subject(s) - norepinephrine transporter , chemistry , positron emission tomography , nuclear medicine , serotonin transporter , binding potential , medicine , norepinephrine , pharmacology , endocrinology , serotonin , dopamine , receptor , biochemistry

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research